In breast cancer, an increase in ICOSL+ B cells following neoadjuvant chemotherapy further enhanced anti‐tumour immunity and efficacy by elevating the ratio of effector T cells to Tregs.27 The gene discussed is ICOSLG; the disease is breast carcinoma.